LB Pharmaceuticals Inc Common Stock carries a market capitalization of 1.32B, placing it among publicly traded companies globally. Its enterprise value stands at 608.41M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 1.32B |
| Enterprise Value | 608.41M |
LB Pharmaceuticals Inc Common Stock currently has 28.68M shares outstanding.
| Shares Outstanding | 28.68M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
| PE Ratio | N/A |
| PS Ratio | N/A |
| PB Ratio | 2.80 |
| P/TBV Ratio | 2.80 |
| P/FCF Ratio | -8.87 |
| P/OCF Ratio | -8.82 |
LB Pharmaceuticals Inc Common Stock maintains a current ratio of 15.08, meaning it holds 15.1x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 15.08 |
| Quick Ratio | 13.91 |
| Debt / Equity | 1.57 |
| Debt / EBITDA | -0.06 |
| Interest Coverage | N/A |
| Return on Equity (ROE) | -32.70 |
| Return on Assets (ROA) | -44.99 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
| Income Tax | 1,000.00 |
| Effective Tax Rate | N/A |
LB Pharmaceuticals Inc Common Stock's stock has gained approximately 155.4375% over the past 52 weeks. The 50-day moving average sits at 42.63, while the 200-day moving average is 31.70.
| Beta (5Y) | N/A |
| 52-Week Price Change | 155.4375% |
| 50-Day Moving Average | 42.63 |
| 200-Day Moving Average | 31.70 |
| Average Volume (20 Days) | N/A |
EBITDA reached -94.79M, while operating income came in at -95.13M.
| Revenue | N/A |
| Gross Profit | N/A |
| Operating Income | -95.13M |
| Pretax Income | -85.68M |
| Net Income | -85.68M |
| EBITDA | -94.79M |
| EBIT | -95.13M |
| Earnings Per Share (EPS) | -3.83 |
LB Pharmaceuticals Inc Common Stock holds 327.79M in cash and equivalents against 5.22M in total debt, resulting in a net debt position of -283.11M. Total book value stands at 332.35M, with working capital of 331.74M providing operational flexibility.
| Cash & Cash Equivalents | 327.79M |
| Total Debt | 5.22M |
| Net Debt | -283.11M |
| Equity (Book Value) | 332.35M |
| Book Value Per Share | 11.59 |
| Working Capital | 331.74M |
LB Pharmaceuticals Inc Common Stock produced -82.39M in operating cash flow over the past twelve months. After subtracting -435,000.00 in capital expenditures, free cash flow totaled -82.83M - equivalent to -3.70 per share.
| Operating Cash Flow | -82.39M |
| Capital Expenditures | -435,000.00 |
| Free Cash Flow | -82.83M |
| FCF Per Share | -3.70 |
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -42.58 |
| FCF Yield | -11.27 |
LB Pharmaceuticals Inc Common Stock posts an Altman Z-Score of 18.49, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 18.49 |